Improving viral vector safety for gene therapies
Drug Discovery World
AUGUST 21, 2024
Integrating vectors such as lentivirus stably insert their payload into the host cell genome, which is advantageous for long-term treatment. The composition of engineered cells in vivo can change over time as clones proliferate at varying rates. The frequency of AAV integration has been estimated at 0.1% to 10% in hepatocytes.
59 
Let's personalize your content